Company RXi Pharmaceuticals Corp Nasdaq
Equities
US74979C5013
Biotechnology & Medical Research
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Robert Bitterman
CEO | Chief Executive Officer | 73 | 12-06-18 |
Caitlin Kontulis
DFI | Director of Finance/CFO | - | - |
James Cardia
CTO | Chief Tech/Sci/R&D Officer | - | 17-09-14 |
Linda M. Mahoney
PRN | Corporate Officer/Principal | - | 22-11-09 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Bitterman
CEO | Chief Executive Officer | 73 | 12-06-18 |
Director/Board Member | 73 | 22-05-01 | |
Curtis Lockshin
BRD | Director/Board Member | 64 | 13-04-17 |
Jonathan Freeman
BRD | Director/Board Member | 56 | 17-06-06 |
Robert Ferrara
BRD | Director/Board Member | 73 | 19-09-30 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 5,454,200 | 5,427,138 ( 99.50 %) | 0 | 99.50 % |
Company contact information
Phio Pharmaceuticals Corp.
11 Apex Drive Suite 300A PMB 2006
01752, Marlborough
+508-767-3861
http://www.phiopharma.comSector
1st Jan change | Capi. | |
---|---|---|
+21.85% | 46.44B | |
+37.63% | 39.1B | |
-8.05% | 38.76B | |
+29.04% | 31.24B | |
-13.75% | 25.8B | |
+10.65% | 25.9B | |
+38.43% | 13.12B | |
-6.92% | 11.32B | |
-12.29% | 10.68B |